Abstract
This multicenter, double-blind, randomized, parallel-group, non-inferiority study compared the efficacy and safety of morinidazole with those of ornidazole in women with pelvic inflammatory disease. Women from 18 hospitals in China received a 14-day course of either intravenous morinidazole, 500 mg twice daily (n = 168), or intravenous ornidazole, 500 mg twice daily (n = 170). A total of 312 of 338 patients in the full analysis set (FAS) (92.3%) were included in the per protocol set (PPS) analyses, 61 (19.6%) of whom were included in the microbiologically valid (MBV) population. The clinical resolution rates in the PPS population at the test of cure (TOC, primary efficacy end point, 7–30 days post-therapy) visit were 96.86% (154/159) for morinidazole and 96.73% (148/153) for ornidazole (95% CI: −3.79% to 4.03%). The bacteriological success rates in the MBV population at the TOC visit were 100% (32/32) for morinidazole and 89.66% (26/29) for ornidazole (95% CI: −16.15% to 11.21%). Drug-related adverse events occurred less frequently with morinidazole (32.74%, 55/168) than with ornidazole (47.06%, 80/170) (p < 0.01). For women with pelvic inflammatory disease, twice-daily morinidazole for 14 days was clinically and bacteriologically as efficacious as twice-daily ornidazole for 14 days, while the former was associated with fewer drug-related adverse events than the latter.
Similar content being viewed by others
References
Ross J (2001) Pelvic inflammatory disease. BMJ 322:658–659
David E (2010) Pelvic inflammatory disease. Obstet Gynecol 116:419–428
French CE, Hughes G, Nicholson A, Yung M, RossJD WT et al (2011) Estimation of the rate of pelvic inflammatory disease diagnoses: trends in England, 2000–2008. Sex Transm Dis 38:158–162
Ross J, Judlin P, Jensen J (2014) 2012 European guideline for the management of pelvic inflammatory disease. Int J STD AIDS 25:1–7
Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC) (2010) Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 59:1–110
Ryan S, Jack DS (2015) Metronidazole for the treatment of vaginal infections. Expert Opin Pharmacother 16(7):1109–1115
AF L (2008) inventor; Jeekai Intellectual Property Limited, assignee. Usage of alpha-(morpholin-1-base) methyl-2-methyl-5-azathio-1-alcohol in preparation of anti-trichomoniasis and anti-ameba medicines. China Patent ZL 200510134254. 3: 636-643
McCormack WM, Nowroozi K, Alpert S et al (1977) Acute pelvic inflammatory disease: characteristics of patients with gonococcal and nongonococcal infection and evaluation of their response to treatment with aqueous procaine penicillin G and spectinomycin hydrochloride. Sex Transm Dis 4:125–131
Duarte R, Fuhrich D, Ross JD (2015) A review of antibiotic therapy for pelvic inflammatory disease. Int J Antimicrob Agents 46:272–277
Brun JL, Graesslin O, Fauconnier A et al (2016) Updated French guidelines for diagnosis and management of pelvic inflammatory disease. Int J Gynaecol Obstet 134:121–125
Wust J (1978) Susceptibiliity of anaerobic bacteria to metronidazole, ornidazole and tinidazole and routine therapy by standardized methods. Antimicrob Agents Chemother 14:609–613
Yu S, Wen A, Xi X (2004) Clinical effect of ornidazole injection in treatment of anaerobic infections in gynecology. Chin J New Drug 13(2):158–160
Bassily S, Farid Z et al (1987) Treatment of intestinal E. histolytica and G. lamblia with metronidazole, tinidazole and ornidazole: a comparative study. J Trop Med Hyg 90(1):9–12
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This study did not receive pharmaceutical company support.
Conflict of Interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the national research committee and with the 1964 Helsinki Declaration and its later amendments.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
C. Cao and A. Luo contributed equally to this work.
Rights and permissions
About this article
Cite this article
Cao, C., Luo, A., Wu, P. et al. Efficacy and safety of morinidazole in pelvic inflammatory disease: results of a multicenter, double-blind, randomized trial. Eur J Clin Microbiol Infect Dis 36, 1225–1230 (2017). https://doi.org/10.1007/s10096-017-2913-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-017-2913-z